The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors (original) (raw)
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
Aaron Cranston
Cancer Research, 2009
View PDFchevron_right
Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
Eddy Yang
Cancer Research, 2012
View PDFchevron_right
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
Joseph Angel de Soto
International Journal of Medical Sciences, 2006
View PDFchevron_right
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Niklas Schultz
Nature, 2007
View PDFchevron_right
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Gerrit Los
JNCI Journal of the National Cancer Institute, 2011
View PDFchevron_right
Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
Lisa Carey
Clinical Cancer Research, 2010
View PDFchevron_right
Poly (ADP-ribose) Polymerase (PARP) Inhibitor and its Role in DNA Repair and Treatment of Triple Negative Breast Cancer
Stephanie Weyrauch
View PDFchevron_right
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
A. Wardley, James Carmichael
The Lancet, 2010
View PDFchevron_right
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells
Mãriâm Mãhmoud
Biochemical Pharmacology, 2021
View PDFchevron_right
The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer
James Carmichael
Breast Care, 2010
View PDFchevron_right
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality
Alessandra Cesano
Molecular medicine (Cambridge, Mass.), 2011
View PDFchevron_right
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Aaron Cranston
Proceedings of the National Academy of Sciences, 2008
View PDFchevron_right
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors
Malka Cohen-Armon
Breast Cancer Research, 2009
View PDFchevron_right
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated
Gerrit Los
2016
View PDFchevron_right
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
Shahneen Sandhu
European Journal of Cancer, 2010
View PDFchevron_right
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
George Pappas-Gogos
Annals of Translational Medicine
View PDFchevron_right
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Michele Moschetta
Diagnostics
View PDFchevron_right
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
Jonathan Keller
Nature communications, 2016
View PDFchevron_right
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
James Carmichael
New England Journal of Medicine, 2009
View PDFchevron_right
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Shahneen Sandhu
CA: A Cancer Journal for Clinicians, 2011
View PDFchevron_right
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice
Ciric To
Cancer prevention research (Philadelphia, Pa.), 2014
View PDFchevron_right
Discovery of 2-{4-[(3 S )-Piperidin-3-yl]phenyl}-2 H -indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
Maria Orsale, Massimiliano Fonsi
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
Karoly Szuhai
Proceedings of the National Academy of Sciences of the United States of America, 2015
View PDFchevron_right
Breaking Ground: PARP Inhibitors and Their Efficacy in Breast Cancer Stages
PROF. EMMANUEL I F E A N Y I OBEAGU
Elite Journal of Medicine, 2024
View PDFchevron_right
Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Nicola Curtin
Cancer discovery, 2017
View PDFchevron_right
PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer
Aaron Cranston
Breast Cancer Research, 2008
View PDFchevron_right
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice
L. Frappart
Oncogene, 2007
View PDFchevron_right
Current and Future Developments of PARP Inhibitors in the Treat ment of Breast and Ovarian Cancer
ingrid boere
Journal of Cancer Science & Therapy, 2018
View PDFchevron_right
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
emanuel NICOLAS
Cancers, 2018
View PDFchevron_right
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells
Ruili Huang
Breast Cancer Research, 2014
View PDFchevron_right
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
Gianluca Tedaldi
International Journal of Molecular Sciences
View PDFchevron_right
Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment
Najim Ameziane
Clinical cancer research : an official journal of the American Association for Cancer Research, 2014
View PDFchevron_right